Henna Rautiainen, Päivi Kärkkäinen, A‐L Karvonen, Heimo Nurmi, Pekka Pikkarainen, Hannu Nuutinen, Martti Färkkilä – 7 March 2005 – Ursodeoxycholic acid (UDCA) is a safe medical therapy for primary biliary cirrhosis (PBC), but its effect on liver histology remains uncertain. Budesonide is a glucocorticoid with high receptor activity and high first‐pass metabolism in liver. We evaluated the combination of budesonide and UDCA on liver histology and compared this with UDCA alone in a 3‐year prospective, randomized, open multicenter study.

Takumi Teratani, Hanako Yamamoto, Kazuhiko Aoyagi, Hiroki Sasaki, Akira Asari, Gary Quinn, Hideo Sasaki, Masaaki Terada, Takahiro Ochiya – 1 March 2005 – The molecules responsible for hepatic differentiation from embryonic stem (ES) cells have yet to be elucidated. Here we have identified growth factors that allow direct hepatic fate‐specification from ES cells by using simple adherent monolayer culture conditions.

Florian Graepler, Barbara Verbeek, Tilmann Graeter, Irina Smirnow, Hwai Loong Kong, Detlef Schuppan, Michael Bauer, Reinhard Vonthein, Michael Gregor, Ulrich M. Lauer – 28 February 2005 – Hepatocellular carcinoma (HCC) is regarded as a suitable target for antiangiogenic strategies. However, antiangiogenic agents aimed at single targets can be neutralized by upregulation of other proangiogenic factors. Therefore, combined approaches addressing at least two angiogenic targets should be more effective.

Markus Reiser, Holger Hinrichsen, Yves Benhamou, Henk W. Reesink, Heiner Wedemeyer, Cristina Avendano, Neus Riba, Chan‐Loi Yong, Gerhard Nehmiz, Gerhard G. Steinmann – 24 February 2005 – BILN‐2061, a specific and potent peptidomimetic inhibitor of the HCV NS3 protease, has recently been shown to markedly lower serum hepatitis C virus (HCV)‐RNA levels in patients chronically infected with HCV genotype 1 in three 2‐day proof of principle studies. The aim of the current study was to assess the antiviral efficacy of BILN‐2061 in patients with genotypes 2 and 3 HCV infection.

Ruud Dirkx, Ilse Vanhorebeek, Katrin Martens, Arno Schad, Markus Grabenbauer, Dariush Fahimi, Peter Declercq, Paul P. Van Veldhoven, Myriam Baes – 24 February 2005 – Peroxisome deficiency in men causes severe pathology in several organs, particularly in the brain and liver, but it is still unknown how metabolic abnormalities trigger these defects. In the present study, a mouse model with hepatocyte‐selective elimination of peroxisomes was generated by inbreeding Pex5‐loxP and albumin‐Cre mice to investigate the consequences of peroxisome deletion on the functioning of hepatocytes.

Fazilat F. Mohammed, Caroline J. Pennington, Zamaneh Kassiri, Jeffrey S. Rubin, Paul D. Soloway, Ulrich Ruther, Dylan R. Edwards, Rama Khokha – 22 February 2005 – Liver regeneration depends on timely restoration of cellular mass while orchestrating structural matrix remodeling. Matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) are known to regulate the extracellular matrix (ECM) turnover and, more recently, the processing of growth factors and cytokines.

Claudio Puoti, Lia Bellis, Roberto Castellacci, Fabrizio Montagnese – 22 February 2005

Giuliana Montosi, Elena Corradini, Cinzia Garuti, Samuele Barelli, Stefania Recalcati, Gaetano Cairo, Linda Valli, Elisa Pignatti, Chiara Vecchi, Francesca Ferrara, Antonello Pietrangelo – 22 February 2005 – Hepcidin, the iron hormone, is produced by the liver in response to iron and inflammation. Its synthesis during inflammation is triggered by cytokines, but the details of iron activation are obscure.

Jay H. Hoofnagle – 22 February 2005

Sigal Kremer‐Tal, Helen Reeves, Goutham Narla, John Martignetti, Scott Friedman – 22 February 2005